Yoshifumi Takahashi

Dr. Yoshifumi Takahashi

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2012 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
YTYoshifumi Takahashi
Yoshifumi Takahashi
TKTakahiro Koyanagi
Takahiro Koyanagi
YSYasuhiro Suzuki
Yasuhiro Suzuki
YSYasushi Saga
Yasushi Saga
NKNaoki Kanomata
Naoki Kanomata
YSYasufumi Sato
Yasufumi Sato
Vasohibin-1 (VASH1) is a VEGF-inducible endothelium-derived angiogenesis inhibitor and VASH2 is its homolog. Our previous analysis revealed that VASH1 is expressed in endothelial cells to terminate angiogenesis, whereas VASH2 is expressed in infiltrating mononuclear cells mobilized from bone marrow to promote angiogenesis in a mouse model of hypoxia-induced subcutaneous angiogenesis. To test the possible involvement of VASH2 in the tumor, we examined human ovarian cancer cells for the presence of VASH2. Immunohistochemical analysis revealed that VASH2 protein was preferentially detected in cancer cells of serous ovarian adenocarcinoma. We then used SKOV-3 and DISS, two representative human serous adenocarcinoma cell lines, and examined the role of VASH2 in the tumor. The knockdown of VASH2 showed little effect on the proliferation of cancer cells in vitro but notably inhibited tumor growth, peritoneal dissemination, and tumor angiogenesis in a murine xenograft model. Next, we stably transfected the human VASH2 gene into two types of murine tumor cells, EL-4 and MLTC-1, in which endogenous VASH2 was absent. When either EL-4 or MLTC-1 cells were inoculated into VASH2 (−/−) mice, the VASH2 transfectants formed bigger tumors when compared with the controls, and the tumor microvessel density was significantly increased. VASH2 stimulated the migration of endothelial cells, and its increased expression in cancer cells is related to the decrease of mir-200b. These results indicate that VASH2 expressed in serous ovarian carcinoma cells promoted tumor growth and peritoneal dissemination by promoting angiogenesis. Mol Cancer Res; 10(9); 1135–46. ©2012 AACR.

23 February 2015 in Archives of Public Health
Verified
Journal Article
Open access
PDF file
HFHiroyuki Fujiwara
Hiroyuki Fujiwara
ASAkihiro Shimoda
Akihiro Shimoda
YIYoshiki Ishikawa
Yoshiki Ishikawa
ATAkiyo Taneichi
Akiyo Taneichi
MOMai Ohashi
Mai Ohashi
MSMitsuaki Suzuki
Mitsuaki Suzuki
In Japan, the cervical cancer screening rate is extremely low. Towards improving the cervical cancer screening rate, encouraging eligible people to make an informed choice, which is a decision-making process that relies on beliefs informed by adequate information about the possible benefits and risks of screening, has attracted increased attention in the public health domain. However, there is concern that providing information on possible risks of screening might prevent deter from participating. In total, 1,912 women aged 20–39 years who had not participated in screening in the fiscal year were selected from a Japanese urban community setting. Participants were randomly divided into 3 groups. Group A received a printed reminder with information about the possible benefits of screening, group B received a printed reminder with information about possible benefits and risks, and group C received a printed reminder with simple information only (control group). Out of 1,912 participants, 169 (8.8%) participated in cervical cancer screening. In the intervention groups, 137 (10.9%) participated in cervical cancer screening, compared to only 32 (4.9%) of the control group (p < 0.001). In addition, logistic regression analysis revealed that there was no significant difference in screening rate between group A and group B (p = 0.372). Providing information on the possible risks of screening may not prevent people from taking part in cervical cancer screening among a Japanese non-adherent population.

7 May 2021 in Thrombosis Research
Verified
Journal Article
Closed access
PDF file
YTYoshifumi Takahashi
Yoshifumi Takahashi
YTYuji Takei
Yuji Takei
ATAkiyo Taneichi
Akiyo Taneichi
STSuzuyo Takahashi
Suzuyo Takahashi
TYTakahiro Yoshiba
Takahiro Yoshiba
HFHiroyuki Fujiwara
Hiroyuki Fujiwara

4 November 2020 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
YTYoshifumi Takahashi
Yoshifumi Takahashi
YTYuji Takei
Yuji Takei
SMShizuo Machida
Shizuo Machida
ATAkiyo Taneichi
Akiyo Taneichi
STSuzuyo Takahashi
Suzuyo Takahashi
HFHiroyuki Fujiwara
Hiroyuki Fujiwara

17 February 2022 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
PDF file
ITIppei Takazawa
Ippei Takazawa
DMDaisuke Matsubara
Daisuke Matsubara
YTYoshifumi Takahashi
Yoshifumi Takahashi
SMShigeki Matsubara
Shigeki Matsubara

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
YTYoshifumi Takahashi
Yoshifumi Takahashi
HFHiroyuki Fujiwara
Hiroyuki Fujiwara
KYKouji Yamamoto
Kouji Yamamoto
MTMasashi Takano
Masashi Takano
MMMorikazu Miyamoto
Morikazu Miyamoto
OIon behalf of the GOTIC-VTE Trial Investigators
on behalf of the GOTIC-VTE Trial Investigators
Takahashi Y, et al. J Gynecol Oncol. 2024 Jan;35:e37. https://doi.org/10.3802/jgo.2024.35.e37